Gay, bisexual, and other men who have sex with men accessing STI clinics: Optimizing HIV PrEP implementation

Hasina Samji1,2,*, Jia Hu3, Michael Otterstatter1,4, Mark Hull5,6, Troy Grennan1,6, David Moore1,3,4, Mark Gilbert1,4, Rob Higgins2,7, Jason Wong1,4

1 British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada, 2 Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada, 3 Public Health and Preventive Medicine, University of Toronto, Toronto, Ontario, Canada, 4 School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada, 5 British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada, 6 Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, 7 School of Public Health and Social Policy, University of Victoria, Victoria, British Columbia, Canada

* Hasina_Samji@sfu.ca

Abstract

Background
Gay, bisexual and other men who have sex with men (gbMSM) who attend STI clinics represent an easily accessible population for promoting HIV prevention interventions. We examined characteristics of gbMSM STI clinic attendees to identify those who could most benefit from pre-exposure prophylaxis (PrEP).

Setting
GbMSM STI clinic attendees in British Columbia (BC), Canada

Methods
A clinical electronic charting system of STI clinics in BC was used to identify gbMSM from 2004 to 2017. Incident HIV cases were defined as testers who had at least one HIV-negative test and a subsequent HIV-positive test. Seroconversion rates were calculated by risk factor variables and by year. Cox proportional hazards regression was used to identify independent predictors of HIV seroconversion.

Results
There were 9,038 gbMSM included, of whom 257 HIV seroconverted over the study period and 8,781 remained negative HIV testers, contributing 650.8 and 29,591.0 person-years to the analysis, respectively. The overall rate of seroconversion was 0.85 per 100 person-years (95% CI: 0.75–0.96). Incidence rates were higher among patients reporting >5 partners in the previous six months, inconsistent condom use, or having a partner living with HIV and who had a previous or concurrent diagnosis of rectal gonorrhea or rectal chlamydia. gbMSM presenting with two STIs such as rectal gonorrhea and syphilis (3.59/100 person-
years [95%CI: 2.33–5.22]) or rectal chlamydia and syphilis (3.01/100 person-years [95%CI: 2.00–4.29]) had the highest incidence rates.

Conclusion

gbMSM with preceding or concurrent rectal STI diagnoses or syphilis had higher rates of HIV seroconversion. The data support the inclusion of specific STI diagnoses as an indication for PrEP.

Introduction

Gay, bisexual, and other men who have sex with men (gbMSM) are disproportionately impacted by HIV in Canada [1, 2], accounting for 50% of new HIV diagnoses in British Columbia (BC), Canada in 2019 [3]. While the absolute number of new diagnoses of HIV among gbMSM has been declining in BC, the proportion of new diagnoses attributable to gbMSM has increased [4]. As such, gbMSM remain a priority group for interventions aimed at reducing HIV seroconversion, including HIV pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), a biomedical prevention measure which has emerged as the standard of care for HIV prevention in specific groups of gbMSM. FTC/TDF for HIV PrEP has been publicly funded in BC since January 2018. It is critical for healthcare systems to identify and prioritize gbMSM at the highest risk of acquiring HIV to maximize the impact of PrEP.

Objective and subjective markers of risk have been explored to determine parameters for PrEP eligibility among gbMSM; the HIV Incidence Risk Index for Men who have Sex with Men (HIRI-MSM) is one such tool that has been validated and used extensively in clinical practice and which has been included in numerous local and national guidelines for establishing PrEP eligibility [5]. However, existing tools and guidelines may miss or not appropriately emphasize risk factors such as recent sexually transmitted infection (STI) diagnosis and the repeated use of HIV postexposure prophylaxis, clear clinical markers that may predict future HIV acquisition and can signal clinicians and health systems to intervene [6–8]. Moreover, many tools rely on the ability of healthcare providers to elicit sensitive information, which may limit their application in settings where providers do not have experience or expertise in working with gbMSM clients. As such, combining risk factor approaches for PrEP eligibility with existing points of contact for individuals at increased risk of HIV seroconversion with the health system (e.g., gbMSM receiving an STI diagnosis) may optimize PrEP delivery [6, 7]. This work builds on these findings through a retrospective analysis of electronic health records from gbMSM in the province of British Columbia (BC), Canada.

STI diagnosis data from repeat testers has been shown to be an efficient means of identifying sub-populations most at risk for HIV and other STIs [1, 9–12]. For example, using an STI clinic sample in New York City, Pathela et al. identified race and condom use as well as incident STIs as highly associated with HIV acquisition; yet, evidence pertaining to the risk of seroconversion in the presence of multiple STIs remains limited [12]. A more nuanced role of risk associated with multiple STIs and HIV acquisition can be used to best target HIV prevention efforts. We examined characteristics of STI clinic attendees to identify gbMSM who could most benefit from PrEP in BC. As STI clinics in BC routinely collect testing and behavioural data, it is both cost-effective and efficient to derive estimates of HIV incidence from these data and to use them to identify groups at highest risk of HIV seroconversion and who therefore

Competing interests: The authors have declared that no competing interests exist.
may benefit most from PrEP. Moreover, STI clinics may be a main point of contact with the health care system for many gbMSM. Lastly, the charting system used by these clinics also served as a comprehensive repository for selected STI diagnoses (e.g., HIV, syphilis) in the province until 2017 (the end point of our analysis) allowing for data from other sources to be included. We examined characteristics of gbMSM whose data is stored in this repository in BC to identify those who could most benefit from PrEP and to evaluate whether our findings corresponded to the Canadian guidelines establishing PrEP eligibility.

Materials and methods

Cohort and study population

The data for our study comes from the STI Information System (STI-IS), an electronic charting system used by STI clinics and street outreach programs operated by the provincial public health system providing sexual health care to clients for screening and diagnosis of STI [13].

Many of the clinics and programs using STI-IS as their charting system were established as a result of activism from community members who fought to have public health resources dedicated to gbMSM given HIV’s disproportionate impact on this community. Especially early in BC’s HIV epidemic, gbMSM experienced a great deal of stigma and homophobia and needed access to testing opportunities that were able to engage with them in a safe and respectful way to improve access to services. Therefore, these clinics are a highly frequented venue for gbMSM seeking testing. These clinics and outreach teams are staffed with nurses and physicians who provide counselling, testing and treatment for STIs, including HIV, in a free and confidential setting. STI-IS is also the database for documentation of all reportable STIs, including chlamydia, gonorrhea, and syphilis, diagnosed in BC. In addition to testing, behavioural risk factor data collection is undertaken by trained nurses and inputted into the STI-IS system at the time of the clinic visit. We included 39 sites distributed across the province’s five regional health authorities. We included patients who were seen between January 1, 2004 and December 31, 2017. We limited our analysis to gbMSM, defined as male patients whose sexual orientation was self-reported as homosexual or bisexual at the time of testing. Patients were included if they had at least two HIV tests, of which the first was negative. Patient visits to a clinic separated by seven days or less were assumed to be follow-up visits and therefore collapsed into a single visit.

Outcome definition

Incident HIV cases were defined by a documented negative HIV test followed by a positive HIV test, during the study period. In calculating the person-years contributed to the time-at-risk, we used the time between each patient’s first negative test and either their last negative test or their estimated date of seroconversion. Given that we cannot know when seroconversion actually occurred, we fixed seroconversion date as the midpoint between the last negative and first positive test, which follows methodology used previously to estimate HIV seroconversion date [1, 13–15].

Explanatory variables

Variables extracted from STI-IS included date of visit, clinic location, age, self-reported condom use pattern, partner HIV status, and number of partners in the previous six months. HIV test information and results and information on reportable STI tests and results (i.e. rectal gonorrhea, rectal chlamydia or syphilis) were also derived from a linkage to the BCCDC Public Health Laboratory. As this was an individual-level analysis and not test-level, we used the
result at the time of the final HIV test (last negative or first positive test) for behavioural variables that potentially vary over time (condom use, partner HIV status, number of partners in prior six months) as the most relevant information for this analysis.

For analysis purposes, we categorized variables as follows: condom usage, past six months: no, inconsistent, consistent, or unknown; number of sexual partners, past six months: less than five partners, five to 14, more than 14, or unknown; HIV status of partners: positive, negative, or unknown; previous (within study period) or concurrent diagnosis (within 7 days of the HIV test) of syphilis, rectal chlamydia, or rectal gonorrhea: yes or no; and age group: 15 to 19, 20 to 24, 25 to 29, 30 to 39, 40 to 59, 60 years and greater (age categories match provincial surveillance reporting groups).

**Statistical analysis**

We present crude incidence rates for the entire study period as well as by year. In calculating annual incidence of HIV, we assigned each seroconversion proportionally to the years within the seroconversion interval, and similarly assigned person-years of follow-up proportionally to the years within an individual’s total period of follow-up. Thus, a case whose seroconversion window is between July 1, 2012 and June 30, 2013 would contribute 0.5 cases to 2012 and 0.5 cases to 2013. For the purpose of understanding annual trends, this proportional assignment approach is preferable to arbitrary assignment of seroconversions to a single year, especially given that many (roughly 40%) seroconversion intervals spanned more than two years, and some spanned up to eight years. Confidence intervals for annual incidence were calculated using the exact method based on Poisson rates. Across the entire study period, we present unadjusted incidence rates by risk factor variable based on binomial regression models with a complementary log-log link, log-transformed person-years as an offset, and confidence intervals calculated using profile-likelihood method [16]. We also divided the study period in two periods (2004–2010 and 2011–2017) to determine whether there were temporal trends associated with the rate of HIV seroconversion over the study period. Specifically, dedicated funding for provincial expansion for support for HIV testing, engagement in HIV care and combination antiretroviral therapy (cART) began in 2010 and may have influenced testing and diagnosis of HIV [17].

Our primary analysis used Cox proportional hazards regression models treating seroconversion as the dependent variable and our behavioural risk factor variables, previous or concurrent STI (syphilis, rectal gonorrhea, or chlamydia) diagnosis, age group, year and testing rate (HIV tests per year of follow-up, log-transformed) as explanatory variables. Individuals who did not seroconvert during our study were censored at their last test date in this analysis. We used forward and backward stepwise elimination with significance levels of P = 0.4 and P = 0.1 for variables to enter and remain in the model, respectively. Model fit and the proportional hazards assumption were assessed using deviance residuals and cumulative sums of martingale residuals [18]. We present unadjusted and adjusted hazard ratios (HR) with 95% confidence intervals for each risk factor, where adjusted values are based on the final model from our stepwise elimination. Additional models were created to examine interactive effects of various STIs. For comparison, we also conducted stepwise elimination of the same explanatory variables using binomial regression models with a complementary log-log link and log-transformed person-years as an offset [19]. Statistical analyses were performed using SAS 9.4 (Cary, NC) [16].

**Ethical approval**

The Clinical Research Ethics Board at the University of British Columbia reviewed and approved the study (H15-01487). This study was a retrospective analysis of medical records.
Data were fully anonymized before analysis and informed consent requirements were waived as data were collected as part of routine public health and clinical services. Minors were also included in this study. Consent was not sought from their parents or guardians and this requirement was waived as the study was an anonymous retrospective analysis of health records.

Results

Summary statistics for our study cohort by seroconversion status of 9,038 gbMSM included in our study are presented in Table 1. The median age was 33 years (interquartile range [IQR]: 27–42) and patients had a median number of three HIV tests (IQR: 2–6). In total, 39 clinics were represented in the dataset, though the majority (90%) of visits occurred at three clinics which were in the Greater Vancouver area. Over the study period, there were 257 HIV seroconversions and 8,781 remained negative HIV testers, contributing 650.8 and 29,591.0 person-years to the analysis, respectively.

The overall rate of seroconversion was 0.85 per 100 person-years (95% CI: 0.75–0.96). Seroconverters were more likely to have an STI diagnosis and an HIV-positive partner. Annual seroconversion rates are shown in Fig 1; there was a trend towards lower rates over the duration of the study period 2004–2017 (p < 0.001), driven primarily by higher rates during the first two years (2004 and 2005). Rates over the remainder of the study period were relatively flat; similarly, the proportion of new diagnoses in the dataset that were gbMSM was consistently high (mean ± SD percent gbMSM: 88.5 ± 11.3%).

Dividing the study period in equal halves, which also corresponds to the launch of an important provincial HIV treatment and prevention initiative in 2010 [17], 97 seroconversions occurred during the early (2004–2010) period and 160 during the late (2011–2017) period, corresponding to rates of 0.96 (95% CI: 0.79–1.17) and 0.79 (95% CI: 0.68–0.92) seroconversions per 100 person-years respectively. Testers in the latter period were younger and had a greater

Table 1. Summary statistics describing the study cohort, comparing HIV seroconverters to negative HIV testers, 2004 to 2017.

| Variable                                | Seroconverters N = 257† | Negative testers N = 8781† | P-value** |
|-----------------------------------------|-------------------------|-----------------------------|-----------|
| Person-years                            | 650.8                   | 29591.0                     | 0.636     |
| Median age (25th-75th percentile)       | 34 (27–41)              | 32 (27–42)                  | 0.229     |
| Age, % (n)                              |                         |                             |           |
| 15–19 years                             | 2.0%                    | 1.2%                        |           |
| 20–24 years                             | 11.3%                   | 13.0%                       |           |
| 25–29 years                             | 19.8%                   | 23.4%                       |           |
| 30–39 years                             | 36.2%                   | 32.2%                       |           |
| 40–59 years                             | 28.4%                   | 26.1%                       |           |
| 60+ years                               | 2.3%                    | 4.2%                        |           |
| Median HIV tests (25th-75th percentile) | 4 (2–7)                 | 3 (2–6)                     | 0.137     |
| % having syphilis diagnosis (n)         | 20.6%                   | 6.7%                        | <0.001    |
| % having rectal chlamydia diagnosis (n) | 24.5%                   | 10.8%                       | <0.001    |
| % having rectal gonorrhea diagnosis (n) | 23.4%                   | 8.2%                        | <0.001    |
| % reporting not using condoms, last 6 months (n†) | 10.9% (N = 165) | 16.3% (N = 5304) | 0.051 |
| % reporting 15 or more partners, last 6 months (n†) | 6.7% (N = 119) | 4.9% (N = 4356) | 0.393 |
| % reporting HIV positive partner, last 6 months (n†) | 31.6% (N = 57) | 10.9% (N = 2007) | <0.001 |

†note: sample sizes for self-reported risk factors are less than the total N due to non-responses; actual number noted in appropriate row

**P-values are from likelihood ratio chi-square tests (proportions) or Wilcoxon tests (medians).
Further descriptive statistics for the early and late periods are shown in Table 2.

Unadjusted incidence rates per 100 person-years are presented in Table 3. Rates were higher for patients: 15–19 years of age (IR: 5.26, 95% CI: 1.92–10.96); with 5 to 14 (IR: 1.33, 95% CI: 0.94–1.81) or ≥15 partners (IR: 1.19, 95% CI: 0.55–2.20) in the previous six months; reporting inconsistent condom use (IR: 1.08, 95% CI: 0.86–1.33); reporting an HIV-positive partner (IR: 1.90, 95% CI: 1.15–2.90), and who ever had a diagnosis of rectal gonorrhea (IR: 1.93, 95% CI: 1.49–2.46), syphilis (IR: 1.91, 95% CI: 1.45–2.47) or rectal chlamydia (IR: 1.56, 95% CI: 1.21–1.97). Patients presenting with two STIs had higher incidence rates; specifically, rectal gonorrhea and syphilis diagnoses (IR: 3.59, 95% CI: 2.33–5.22), rectal chlamydia and

| Variable                        | Early period (2004–2010) | Late period (2011–2017) | P-value** |
|---------------------------------|--------------------------|--------------------------|-----------|
| Seroconversions/person-years    | 0.95 per 100 person-years (97/10117) | 0.80 per 100 person-years (160/20108) | 0.149     |
| Median age (25th -75th percentile) | 34 (16–78)               | 32 (16–90)               | 0.043     |
| Median HIV tests (range)        | 2 (2–22)                 | 4 (2–56)                 | <0.001    |
| % reporting not using condoms, last 6 months (n°) | 15.6% (168/1075) | 16.3% (715/3679) | 0.606 |
| % reporting ≥15 partners, last 6 months (n°) | 5.4% (52/965) | 4.8% (170/3510) | 0.494 |
| % reporting HIV positive partner, last 6 months (n°) | 12.7% (37/291) | 11.3% (200/1773) | 0.482 |

* note: sample sizes for self-reported risk factors are less than the total n due to non-responses
** P-values are from chi-square tests (proportions) or Wilcoxon tests (medians).

https://doi.org/10.1371/journal.pone.0261705.t002
syphilis diagnoses (IR: 3.01, 95% CI: 2.00–4.29), and rectal gonorrhea diagnosis and rectal chlamydia (IR: 2.43, 95% CI: 1.70–3.34). Lowest rates were observed for patients reporting no condom use, those with an HIV-negative partner, those aged 60 years and older, and those without a previous STI diagnosis.

Analysis of risk factor variables using Cox proportional hazards regression found that HIV seroconversion was independently associated with having a previous or concurrent diagnosis of syphilis (adjusted HR: 1.98; 95%CI: 1.43–2.75), rectal gonorrhea (aHR: 1.83; 95%CI: 1.30–2.57) or rectal chlamydia (aHR: 1.71, 95% CI: 1.21–2.41). Reporting an HIV-positive sexual partner was also significantly associated with HIV seroconversion (aHR: 1.98; 95%CI: 1.12–3.49). In contrast, the number of recent (last 6 months) sexual partners, recent condom usage and age were no longer statistically significant after adjusting for STI diagnosis and an HIV-positive sexual partner and were excluded from the final model. Regression statistics are shown in Table 4.

Additional regression analyses were conducted to explore the effect of having multiple previous or concurrent STI diagnoses on HIV seroconversion. Of the 257 individuals with HIV seroconversion, 23 (8.9%) had been diagnosed with both rectal gonorrhea and syphilis, 33 (12.8%) with rectal gonorrhea and rectal chlamydia, and 26 (10.1%) with syphilis and rectal chlamydia. Among HIV seroconverters, roughly 80% of STI diagnoses (syphilis, rectal chlamydia, and rectal gonorrhea) were observed in those with a previous or concurrent STI diagnosis.

### Table 3. Unadjusted incidence rates for HIV seroconversion, by risk factor, during the study period 2004–2017 (N = 9,038 individuals).

| Risk factor                          | Incidence rate per 100 person-years (95% CI) |
|--------------------------------------|---------------------------------------------|
| **Condom use**                       |                                             |
| Consistent                           | 0.87 (0.68–1.09)                            |
| No                                   | 0.54 (0.33–0.83)                            |
| Inconsistent                         | 1.08 (0.86–1.33)                            |
| Unknown                              | 0.79 (0.64–0.97)                            |
| **Sexual partners**                  |                                             |
| < 5                                  | 0.70 (0.55–0.87)                            |
| 5 to 14                              | 1.33 (0.94–1.81)                            |
| 15 or more                           | 1.19 (0.55–2.20)                            |
| **Previous or concurrent STI**       |                                             |
| None                                 | 0.65 (0.55–0.76)                            |
| Syphilis                             | 1.91 (1.45–2.47)                            |
| Rectal chlamydia                     | 1.56 (1.21–1.97)                            |
| Rectal gonorrhea                     | 1.93 (1.49–2.46)                            |
| Syphilis and rectal chlamydia        | 3.01 (2.00–4.29)                            |
| Syphilis and rectal gonorrhea        | 3.59 (2.33–5.22)                            |
| Rectal chlamydia and rectal gonorrhea| 2.43 (1.70–3.34)                            |
| **Partner status**                   |                                             |
| HIV positive                         | 1.90 (1.15–2.90)                            |
| HIV negative                         | 0.56 (0.40–0.75)                            |
| **Age group**                        |                                             |
| 15 to 19                             | 5.26 (1.92–10.96)                           |
| 20 to 24                             | 1.53 (1.04–2.15)                            |
| 25 to 29                             | 0.97 (0.73–1.26)                            |
| 30 to 39                             | 0.89 (0.72–1.08)                            |
| 40 to 59                             | 0.70 (0.55–0.87)                            |
| 60 and over                          | 0.31 (0.12–0.62)                            |

https://doi.org/10.1371/journal.pone.0261705.t003
chlamydia and rectal gonorrhea) occurred within 12 months prior to HIV diagnosis; the remaining occurred within seven days of HIV diagnosis and were considered concurrent with HIV. Risk factor results from the binomial regression models were consistent with those from our proportional hazards models and are not discussed further.

**Discussion**

Our study investigated HIV seroconversion risk among gbMSM in the STI-IS database over a 14-year period to identify populations who would benefit most from PrEP. In adjusted models we found that reporting an HIV-positive partner and previous or concurrent diagnosis of rectal gonorrhea, syphilis or rectal chlamydia increased the risk of HIV seroconversion. HIV incidence was between 3–6 times higher among individuals with multiple previous or concurrent bacterial STIs compared to those without a previous STI diagnosis during the study period. In the Canadian context, preliminary findings from our work informed national and provincial eligibility guidelines for PrEP initiation to include gbMSM diagnosed with infectious syphilis or rectal bacterial STI in the past 12 months [6, 20]. There were 257 seroconversions among more than 9,000 individuals resulting in an overall HIV incidence rate of 0.85 per 100 person-years. Annual incidence rates remained largely consistent over the study period from 2004 to 2017, as did patient characteristics such as number of sexual partners, median age, and condom use, though the median number of tests increased over time.

Our findings underscore the need to prioritize gbMSM with a history of bacterial STIs for additional prevention resources, such as counselling, education, monitoring; referral for biomedical strategies such as PrEP; and inclusion in criteria being used to determine eligibility for PrEP initiation. As many STIs are reportable in BC and elsewhere, with follow-up mandated.
by the healthcare system, STI diagnosis represents a natural opportunity to connect with patients at risk of seroconversion and perform an assessment for PrEP eligibility. Moreover, we found that existing criteria for PrEP eligibility such as condom use and number of sexual partners were not predictive of HIV seroconversion; these subjective criteria may also be misleading for patients to assess their own risk of acquisition.

Based on these findings, objective clinical markers such as previous STI diagnoses should be prioritized and trigger conversations about PrEP referral, with STI clinics at the forefront of PrEP screening and referral. Additionally, these findings indicate that further research into altering PrEP eligibility criteria for gbMSM is warranted. Current guidelines require that gbMSM report having had condomless anal intercourse in addition to a rectal bacterial STI diagnosis to be eligible. While some prescribing physicians may be more lenient and flexible in their referral PrEP initiation, less experienced clinicians may more strictly adhere to these guidelines, potentially excluding patients who would benefit from PrEP. As well, due to historical stigma experienced by gbMSM in relation to HIV/AIDS, some clients may not be willing to disclose that they are engaging in condomless anal intercourse. Thus, an objective measure of risk—such as a recent rectal bacterial STI diagnosis—may more accurately capture the risk of HIV acquisition that a client is experiencing and better protect those who are more vulnerable. Such a change in guidelines would ideally position STI clinics as PrEP referral sites, with protocols in place prioritizing PrEP initiation among clients with bacterial STIs.

In addition, though the sample size was small, we found that younger gbMSM between the ages of 15 to 24 years had relatively high HIV incidence rates, supporting PrEP eligibility criteria prioritizing younger gbMSM. Not only are younger, minority gbMSM at higher risk of seroconversion [12, 21, 22] but screening for HIV and other STIs at STI clinics may be one of their few points of engagement with the healthcare system. Thus, STI clinics may be optimally suited to target those with a history of STIs and younger gbMSM in increased risk reduction counseling and referral for PrEP [23].

Our study identified a doubling of risk of HIV seroconversion for individuals with a previous or concurrent bacterial STI. Similarly, a case control study of gbMSM in a Seattle clinic identified a more than two-fold increase in the odds of HIV seroconversion associated with rectal gonorrhea and concurrent rectal chlamydia [24], while Desai et al.’s study in England examining acute bacterial STI diagnosis in the previous year found a four-fold higher risk of HIV seroconversion among those with syphilis and a two-fold increase related to gonorrhea [25]. In a study based in New York City, annual HIV incidence was higher among gbMSM with rectal infections (6.7%) than gbMSM without rectal infections (2.5%), and a study of gbMSM in Atlanta study found that rectal STIs were associated with a more than two-fold risk of subsequent HIV acquisition [15].

HIV seroconversion was considerably higher in our study for gbMSM with two bacterial STIs occurring concurrently, results that are corroborated in a small study of gbMSM that found an 8-fold greater risk of seroconversion with two or more prior infections of gonorrhea or chlamydia [26]. Another American study found a 2.46 [95%CI: 2.01–3.00] times increased risk of HIV diagnosis among men with primary and secondary syphilis who also had a concurrent or subsequent bacterial STI versus those with only syphilis [12]. More work is needed using larger samples to confirm indications of increased risk associated with multiple STI co- or subsequent occurrence given physiological evidence linking bacterial STIs to increased risk of HIV seroconversion, likely through inflammation processes that increase mucosal disruption [24]. Increased understanding of biological and behavioural mechanisms underpinning transmission risk associated with multiple STI infections will also elucidate the nature and duration of the risk associated with each bacterial STI.
Heightened seroconversion risk among individuals with a bacterial STIs is especially concerning in the context of the ongoing syphilis epidemics among gbMSM in urban centres in North American and Europe [27], as well as increasing rates of gonorrhea and chlamydia [22, 28]. These increases have been explained as a return to pre-HIV high STI incidence in gbMSM populations as worries about HIV risk wane in the context of effective antiretroviral treatment and prevention fatigue [29]. The promise of PrEP in clinical and applied settings [30–33] in reducing risk of HIV acquisition, as well as increased STI testing, will likely reinforce this increasing trend of bacterial STIs among gbMSM, with potential implications for downstream increases in the broader population. As such, novel prevention tools such as chemoprophylaxis for bacterial STIs that address increases in STI concomitant with HIV incidence decrease may be warranted [34–36].

Our estimate of HIV incidence is comparable to a mathematical modeling study estimating population-level incidence among gbMSM in England and Wales from 2001 to 2007 (0.9%) [37] and lower compared to studies of gbMSM tested in STI clinics such as a study of repeat testers in a cohort of gbMSM testing in STI clinics in England (2012 to 2013), which found an HIV incidence of 2.0 per 100 person-years [25], and American (2007 to 2012) and Australian (2007 to 2013) studies estimating HIV incidence of 2.4 and 1.3 per 100 person-years, respectively [12, 38]. Findings are also in line with a cohort study of gbMSM conducted between 2012–2015 in Vancouver, BC, which reported an incidence rate of 1.1 per 100 person-years [39] but lower compared to an incidence estimate of 2.8 per 100 person-years in a cohort of gbMSM in Lisbon from 2011 to 2014 [40], 2.4 per 100 person-years in Barcelona from 2008 to 2011 [41], and a 1.6 per 100 person-years in a study that combined empirical methods in San Francisco in 2010 [42].

Ultimately, in a promising era where considerable progress has been achieved in reaching global HIV elimination goals, reducing HIV incidence among gbMSM remains a priority. It is possible that rising STI trends among gbMSM in BC are off-setting any decreases in HIV incidence due to cART [28]. As well, PrEP was not provincially publicly funded in BC until January 2018; as such, we may see greater reductions in HIV incidence as the program expands, as seen in other jurisdictions such as in New South Wales, Australia, where a 25.1% reduction in HIV diagnoses was observed in the 12 month period after PrEP roll-out [43, 44]. To maximize this potential reduction, bacterial STIs should be given stronger consideration in PrEP eligibility criteria.

There are several limitations to our study. Firstly, repeat testing data results in interval censoring in which disease onset occurs sometime between a last negative screen and HIV diagnosis; this is a known limitation of this type of data. Left censoring, when an outcome occurs prior to the study observation period, may also occur if disease was prevalent but not yet diagnosed. Those who are more frequently tested such as individuals frequenting STI clinics are likely at higher risk of HIV seroconversion than the broader community, and therefore incidence estimates may not be generalizable to the wider population [45]; as well, our study did not include individuals with only one HIV test were not included in the analysis, leading to an underestimation of HIV incidence as seroconversions associated with these single testers were not included. Using behavioural data at the time of last test assumes that sexual risk variables are static and does not reflect possible changes in sexual trajectories.

Lastly, given the intersecting epidemics and shared sexual transmission routes of bacterial STIs and HIV, improved characterization of contextual factors not collected in this study such
as unstable housing, stigma, poverty, social isolation, mental health status, interpersonal violence and substance use and their combined effects on risk of HIV acquisition may yield dividends in reducing incidence of all of these diseases. Such a syndemic approach has been instrumental in elucidating interacting factors leading to increased risk of HIV among populations of gbMSM [4, 46] and has been recently used to understand the risk of syphilis acquisition in BC [47]. While biomedical interventions such as pre- and post-exposure prophylaxis, male circumcision and most recently, long-acting Injectable antiretrovirals [48] have either demonstrated efficacy or potential promise for prevention, fundamental causes underlying risk behaviours for HIV acquisition must continue to be addressed.

We found that objective measures such as previous STI infection were better at predicting risk of HIV seroconversion than self-reported measures such as condom use or number of sexual partners. Screening tools may benefit from considering these parameters in their indices and eligibility criteria. As gbMSM with a previous or concurrent STI diagnosis and those with an HIV-positive partner had a noticeably higher risk of seroconversion, they should be prioritized for interventions aimed at reducing HIV and STI incidence.

Acknowledgments
We gratefully acknowledge the residents of British Columbia whose data are integrated in this analysis, as well as Gaelen Snell for his assistance with formatting the manuscript.

Author Contributions
Conceptualization: Hasina Samji, Mark Hull, David Moore, Jason Wong.
Data curation: Hasina Samji.
Formal analysis: Jia Hu, Michael Otterstatter.
Investigation: Hasina Samji.
Methodology: Hasina Samji, Michael Otterstatter, Jason Wong.
Project administration: Hasina Samji.
Supervision: Hasina Samji.
Writing – original draft: Hasina Samji, Jia Hu, Michael Otterstatter.
Writing – review & editing: Hasina Samji, Jia Hu, Michael Otterstatter, Mark Hull, Troy Grennan, David Moore, Mark Gilbert, Rob Higgins, Jason Wong.

References
1. Calzavara L, LAN B, Major C. Increases in HIV incidence among men who have sex with men undergoing repeat diagnostic HIV testing in Ontario, Canada. AIDS. 2002; 16(12):1655–61. https://doi.org/10.1097/00002030-200208160-00011 PMID: 12172087
2. Sullivan PS, Hamouda O, Delpech V. Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996–2005. Ann Epidemiol. 2009; 19 (6):423–31. https://doi.org/10.1016/j.annepidem.2009.03.004 PMID: 19460672
3. BC Centre for Excellence in HIV/AIDS. HIV Monitoring Semi-Annual Report for British Columbia: Fourth Quarter 2020. Vancouver, BC, Canada; 2020. http://stophivaid.ca/qmr/2020-Q4/#/bc.
4. British Columbia Centre for Disease Control. HIV in British Columbia: Annual Surveillance Report 2016. 2016. http://www.bccdc.ca/search?k=hivannualreport.
5. Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a Clinical Screening Index Predictive of Incident HIV Infection Among Men Who Have Sex With Men in the United States. JAIDS J Acquir Immune Defic Syndr. 2012; 60(4):421–427. https://doi.org/10.1097/QAI.0b013e318256b2f6 PMID: 22487585
6. Tan DHS, Hull MW, Yoong D. Canadian guidelines on HIV pre-exposure prophylaxis and non-occupational post-exposure prophylaxis. *CMAJ*. 2017; 189(47).

7. Wilton J, Mishra S, Tan DHS. Considerations for Using the HiRI-MSM Screening Tool to Identify MSM Who Would Benefit Most From PrEP. *J Acquir Immune Defic Syndr*. 2017; 76(2). https://doi.org/10.1097/QAI.0000000000001472 PMID: 28903127

8. *Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2017 Update: A Clinical Practice Guideline*. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.

9. Kellogg TA, Loeb L, Dilley J. Comparison of three methods to measure HIV incidence among persons seeking voluntary, anonymous counseling and testing. *J Acquir Immune Defic Syndr*. 2005; 39(1):112–20. https://doi.org/10.1097/01.qai.0000144444.44518.a3 PMID: 15851921

10. McFarland W, Kellogg TA, Dilley J. Estimation of human immunodeficiency virus (HIV) seroconversion among repeat anonymous testers in San Francisco. *Am J Epidemiol*. 1997; 146(8):662–4. https://doi.org/10.1093/oxfordjournals.aje.a009332 PMID: 9345120

11. Weinstock H, Sweeney S, Satten GA. HIV seroconversion and risk factors among patients repeatedly tested for HIV attending sexually transmitted disease clinics in the United States, 1991 to 1996. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998; 19(5):506–12. https://doi.org/10.1002/00011 PMID: 9859965

12. Pathela P, Jamison K, Braunstein SL, Schillinger JA, Varma JK, Blank S. Incidence and Predictors of HIV Infection Among Men Who Have Sex with Men Attending Public Sexually Transmitted Disease Clinics, New York City, 2007–2012. *AIDS Behav*. 2017; 21(5):1444–1451. https://doi.org/10.1007/s10461-016-1499-2 PMID: 27448826

13. Ling DI, Janjua NZ, Wong S. Sexually transmitted infection trends among gay or bisexual men from a clinic-based sentinel surveillance system in British Columbia, Canada. *Sex Transm Dis*. 2015; 42(3):153–9. https://doi.org/10.1097/OLQ.000000000000250 PMID: 25668648

14. Kitayaporn D, Uneklabh C, Weniger BG. HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. *AIDS*. 1994; 8(10):1443–50. https://doi.org/10.1007/10000230-19941000-0011 PMID: 7818815

15. Kelley CF, Vaughan AS, Luisi N. The Effect of High Rates of Bacterial Sexually Transmitted Infections on HIV Incidence in a Cohort of Black and White Men Who Have Sex with Men in Atlanta, Georgia. *AIDS Res Hum Retroviruses*. 2015; 31(6):587–92. https://doi.org/10.1089/AID.2015.0013 PMID: 25719950

16. SAS Institute Inc. SAS [computer program]. 2012.

17. British Columbia Ministry of Health. *From Hope to Health: Towards an AIDS-Free Generation*. Victoria, BC; 2012.

18. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. *Biometrika*. 1993; 80(3):557–72.

19. Jewell NP, Shiboski SC. Statistical analysis of HIV infectivity based on partner studies. *Biometrics*. 1990; 46(4):1133–50. PMID: 2085629

20. British Columbia Centre for Excellence in HIV/AIDS. *Guidance for the Use of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV Acquisition in British Columbia*. Vancouver, BC; 2020.

21. Prejean J, Song R, Hernandez A. Estimated HIV incidence in the United States, 2006–2009. *PLoS One*. 2011; 6(8). https://doi.org/10.1371/journal.pone.0017502 PMID: 21826193

22. Reported STDs in the United States. 2016. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/std-trends-508.pdf.

23. Valdiserri RO, Holtgrave DR. Pre-exposure Prophylaxis for HIV Infection: Preventing Disease or Promoting Sexual Health? *J Community Heal*. 2019. https://doi.org/10.1007/s10900-018-00616-3 PMID: 30617734

24. Barbee LA, Khosropour CM, Dombrowski JC. New Human Immunodeficiency Virus Diagnosis Independently Associated With Rectal Gonorrhea and Chlamydia in Men Who Have Sex With Men. *Sex Transm Dis*. 2017; 44(7):385–9. https://doi.org/10.1097/OLQ.00000000000000614 PMID: 28698786

25. Desai S, Nardone A, Hughes G. HIV incidence in an open national cohort of men who have sex with men attending sexually transmitted infection clinics in England. *HIV Med*. 2017; 18(9):615–22. https://doi.org/10.1111/hiv.12498 PMID: 28127837

26. Bernstein KT, Marcus JL, Nieri G. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. *J Acquir Immune Defic Syndr*. 2010; 53:537–43. https://doi.org/10.1097/QAI.0b013e3181c3e59 PMID: 19995075

27. Kitayama K, Segura ER, Lake JE. Syphilis in the Americas: a protocol for a systematic review of syphilis prevalence and incidence in four high-risk groups, 1980–2016. *Syst Rev*. 2017; 6(1). https://doi.org/10.1186/s13643-017-0595-3 PMID: 29017592
28. British Columbia Centre for Disease Control. STI in British Columbia: Annual Surveillance Report. 2016. http://www.bccdc.ca/search?k=stiannualreport.

29. Stenger MR, Baral S, Shahman S. As through a glass, darkly: the future of sexually transmissible infections among gay, bisexual and other men who have sex with men. Sex Heal. 2017; 14(1):18–27. https://doi.org/10.1077/S16104 PMID: 27585033

30. Grant RM, Lama JR A, P. L., Med NEJ. Preexposure prophylaxis for HIV prevention in men who have sex with men. 2010; 363(27):2587–99. https://doi.org/10.1056/NEJMoa1011205 PMID: 21091279

31. Volk JE, Marcus JL, Phengrasamy T. No New HIV Infections With Increasing Use of Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis. 2015; 61(10):1601–3. https://doi.org/10.1093/cid/cid778 PMID: 26334052

32. Liu AY, Cohen SE, Vittinghoff E. Preexposure Prophylaxis for HIV Infection Integrated With Municipal and Community-Based Sexual Health Services. JAMA Intern Med. 2016; 176(1):75–84. https://doi.org/10.1001/jamainternmed.2015.4683 PMID: 26571482

33. McCormack S, Dunn DT, Desai M. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016; 387(10013):53–60. https://doi.org/10.1016/S0140-6736(15)00056-2 PMID: 26364263

34. Scott HM, Klausner JD. Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US. AIDS Res Ther. 2016; 13(5). https://doi.org/10.1186/s12981-016-0089-8 PMID: 26793265

35. Bolan RK, Beymer MR, Weiss RE. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015; 42:98–103. https://doi.org/10.1097/OLQ.0000000000000216 PMID: 25585069

36. Molina JM, Chareau I, Chidiac C. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018; 18(3):308–17. https://doi.org/10.1016/S1473-3099(17)30725-9 PMID: 29229440

37. Presanis AM, De AD, Goubar A. Bayesian evidence synthesis for a transmission dynamic model for HIV among men who have sex with men. Biostatistics. 2011; 12:666–81. https://doi.org/10.1093/biostatistics/kx006 PMID: 21525422

38. Cheung KT, Fairley CK, Read TR. HIV Incidence and Predictors of Incident HIV among Men Who Have Sex With Men Attending a Sexual Health Clinic in Melbourne, Australia. PLoS One. 2016; 11(5). https://doi.org/10.1371/journal.pone.0156160 PMID: 27219005

39. Lachowsky N, Cui Z, Sereda P. HIV Incidence Rate and Predictors Among Gay and other Men Who Have Sex With Men: first results, 2011–2014. In: 25th Annual Canadian Conference on HIV/AIDS Research. Winnipeg, Canada; 2016.

40. Meireles P, Lucas R, Carvalho C. Incident risk factors as predictors of HIV seroconversion in the Lisbon cohort of men who have sex with men: first results, 2011–2014. Euro Surveill. 2015; 20(14). https://doi.org/10.2807/1560-7917.es2015.20.14.21091 PMID: 25841515

41. Ferrer L, Loureiro E, Meulbroek M. High HIV incidence among men who have sex with men attending a community-based voluntary counselling and testing service in Barcelona, Spain: results from the ITACA cohort. Sex Transm Infect. 2016; 92(1):70–5. https://doi.org/10.1136/sextrans-2015-052042 PMID: 26136507

42. Raymond HF, Bereknyei S, Berglas N. Estimating population size, HIV prevalence and HIV incidence among men who have sex with men: a case example of synthesising multiple empirical data sources and methods in San Francisco. Sex Transm Infect. 2013; 89(5):389–7. https://doi.org/10.1136/sextrans-2012-050675 PMID: 23620133

43. Grulich AE, Guy R, Amin J. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018; 5(11). https://doi.org/10.1016/S2352-3018(18)30215-7 PMID: 30343026

44. Buchbinder SP, Cohen SE, Hecht J. Getting to zero new HIV diagnoses in San Francisco: what will it take? In: Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA; 2018.

45. Kent CK, Chaw JK, Kohn RP. Studies relying on passive retrospective cohorts developed from health services data provide biased estimates of incidence of sexually transmitted infections. Sex Transm Dis. 2004; 31(10):596–600. https://doi.org/10.1097/01.OLQ.0000140051.93104.32 PMID: 15388996

46. Stall R, Mills TC, Williamson J. Association of co-occurring psychosocial health problems and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public Heal. 2003; 93(6):939–42. https://doi.org/10.2105/ajph.93.6.939 PMID: 12773359
47. Ferlatte O, Salway T, Samji H. An Application of Syndemic Theory to Identify Drivers of the Syphilis Epidemic among Gay, Bisexual, and other Men who have Sex with Men. *Sex Transm Dis.* 2017.

48. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. *Lancet.* 2017; 390(10101):1499–510. https://doi.org/10.1016/S0140-6736(17)31917-7 PMID: 28750935